NCT00102011 (00-046) is a Phase 3 clinical trial of annual screening in Colorectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT00102011?

NCT00102011 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT00102011?

Interventions in NCT00102011: annual screening, fecal occult blood test, screening colonoscopy, standard follow-up care.

What condition does NCT00102011 study?

NCT00102011 studies Colorectal Cancer.

Is NCT00102011 still recruiting?

NCT00102011 is currently completed. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT00102011: 00-046

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer

Completed Phase 3 Last updated 9 March 2026

What this trial tests

Phase 3 trial testing annual screening in Colorectal Cancer in 4,952 participants. Completed in 5 March 2026.

Timeline

25 May 2000

Primary endpoint
5 March 2026

5 March 2026

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	4,952
Start date	25 May 2000
Primary completion	5 March 2026
Estimated completion	5 March 2026
Sites	4 locations across United States

Drugs / interventions tested

annual screening
fecal occult blood test
screening colonoscopy — full drug profile →
standard follow-up care

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

Adults 40 to 69, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Screening tests, such as colonoscopy and fecal occult blood test, may help doctors find tumor cells early and plan better treatment for colorectal cancer. PURPOSE: This randomized phase III trial is studying colonoscopy to see how well it works compared to fecal occult blood test in screening healthy participants for colorectal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test.
Zauber AG, Winawer SJ, O'Brien MJ, Mills GM, et al · · 2023 · cited 16× · PMID 36948424 · DOI 10.1053/j.gastro.2023.03.206
Colorectal cancer screening.
Hayee BH, Chung-Faye G. · · 2006 · cited 1× · PMID 17080891 · DOI 10.7861/clinmedicine.6-5-453

Verify or expand the search:

Other trials of annual screening

Trials testing the same drug.

NCT00058032 — CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women · NA · completed

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00102011 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00102011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing